Clinical and economic impact of implementing OVIVA criteria on patients with bone and joint infections in outpatient parenteral antimicrobial therapy

Michael Marks, Lucy C.K. Bell, Imogen Jones, Tommy Rampling, Katharina Kranzer, Stephen Morris-Jones, Sarah Logan, Gabriele Pollara*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)

Abstract

The OVIVA study demonstrated noninferiority for managing bone and joint infections (BJIs) with oral antibiotics. We report that 79.7% of OPAT patients being treated for BJIs at our center would be eligible for oral antibiotics, saving a median (IQR) 19.5 IV-antibiotic days (8.5-37) and GBP 1234 (569-2594) per patient.

Original languageEnglish
Pages (from-to)207-210
Number of pages4
JournalClinical Infectious Diseases
Volume71
Issue number1
DOIs
Publication statusPublished - 1 Jul 2020
Externally publishedYes

Bibliographical note

Funding Information:
This work was supported by the Wellcome Trust (grant numbers WT101766 to G. P. and WT102807 to M. M.). All authors were supported by the University College London Hospitals Comprehensive Biomedical Research Centre Infection Theme.

Publisher Copyright:
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.

Keywords

  • IV antibiotics
  • OPAT
  • OVIVA

Fingerprint

Dive into the research topics of 'Clinical and economic impact of implementing OVIVA criteria on patients with bone and joint infections in outpatient parenteral antimicrobial therapy'. Together they form a unique fingerprint.

Cite this